Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice

Journal of Lipid Research

Volumn 53, Issue 8, 2012, Pages 1654-1661

  Fattori, Elena ^a   Cappelletti, Manuela ^a   Lo Surdo, Paola ^a   Calzetta, Alessandra ^a   Bendtsen, Claus ^a   Ni, Yan G ^b   Pandit, Shilpa ^b   Sitlani, Ayesha ^b   Mesiti, Giuseppe ^a   Carfí, Andrea ^a   Monaci, Paolo ^a  

^a IRBM   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Active immunization; Animal model systems; Cholesterol lowering treatments; In vivo functional validation

Indexed keywords

CHOLESTEROL; CPG OLIGODEOXYNUCLEOTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLASMID DNA; PROPROTEIN CONVERTASE SUBTILISIN LIKE KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CROSS REACTION; ENZYME INHIBITION; FEMALE; GENE PRODUCT; GENE SILENCING; HUMORAL IMMUNITY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING;

ANIMALS; ANTIBODIES; CHOLESTEROL, LDL; FEMALE; HEK293 CELLS; HUMANS; IMMUNIZATION; LIVER; MICE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84863797984     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M028340     Document Type: Article

References (44)

1. DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22: 151-185. (Pubitemid 36279392)
2. Schäfer, S., and P. Kolkhof. 2008. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov. Today. 13: 913-916.
3. Giacomini, K. M., R. M. Krauss, D. M. Roden, M. Eichelbaum, M. R. Hayden, and Y. Nakamura. 2007. When good drugs go bad. Nature. 446: 975-977. (Pubitemid 46676037)
4. Persidis, A. 2000. Data mining in biotechnology. Nat. Biotechnol. 18: 237-238. (Pubitemid 30091191)
5. Butcher, E. C., E. L. Berg, and E. J. Kunkel. 2004. Systems biology in drug discovery. Nat. Biotechnol. 22: 1253-1259. (Pubitemid 39336778)
6. Xia, X. G., H. Zhou, and Z. Xu. 2006. Transgenic RNAi: accelerating and expanding reverse genetics in mammals. Transgenic Res. 15: 271-275. (Pubitemid 43901486)
7. Lindsay, M. A. 2003. Target discovery. Nat. Rev. Drug Discov. 2: 831-838. (Pubitemid 37361815)
8. Chatterjee-Kishore, M., and C. P. Miller. 2005. Exploring the sounds of silence: RNAi-mediated gene silencing for target identifi- cation and validation. Drug Discov. Today. 10: 1559-1565. (Pubitemid 41527199)
9. Lloyd-Jones, D., R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, et al. 2009. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119: 480-486.
10. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2009. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50: S172-S177.
11. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2007. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32: 71-77. (Pubitemid 46199197)
12. Seidah, N. G. 2009. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets. 13: 19-28.
13. Costet, P., M. Krempf, and B. Cariou. 2008. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem. Sci. 33: 426-434.
14. Henrich, S., I. Lindberg, W. Bode, and M. E. Than. 2005. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J. Mol. Biol. 345: 211-227. (Pubitemid 39574845)
15. Seidah, N. G., and A. Prat. 2007. The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85: 685-696. (Pubitemid 47063524)
16. Zaid, A., A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland, J. Hamelin, M. Tremblay, H. Jacques, W. Jin, J. Davignon, et al. 2008. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 48: 646-654.
17. Piper, D. E., S. Jackson, Q. Liu, W. G. Romanow, S. Shetterly, S. T. Thibault, B. Shan, and N. P. Walker. 2007. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 15: 545-552. (Pubitemid 46702689)
18. Hampton, E. N., M. W. Knuth, J. Li, J. L. Harris, S. A. Lesley, and G. Spraggon. 2007. The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. USA. 104: 14604-14609. (Pubitemid 350003191)
19. Cunningham, D., D. E. Danley, K. F. Geoghegan, M. C. Griffor, J. L. Hawkins, T. A. Subashi, A. H. Varghese, M. J. Ammirati, J. S. Culp, L. R. Hoth, et al. 2007. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14: 413-419. (Pubitemid 46685885)
20. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875. (Pubitemid 39625767)
21. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933. (Pubitemid 36183932)
22. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116: 2995-3005. (Pubitemid 44684484)
23. Cameron, J., O. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge, and T. P. Leren. 2006. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15: 1551-1558.
24. Fisher, T. S., P. Lo Surdo, S. Pandit, M. Mattu, J. C. Santoro, D. Wisniewski, R. T. Cummings, A. Calzetta, R. M. Cubbon, P. A. Fischer, et al. 2007. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem. 282: 20502-20512. (Pubitemid 47100016)
25. Zhang, D. W., R. Garuti, W. J. Tang, J. C. Cohen, and H. H. Hobbs. 2008. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 105: 13045-13050.
26. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105: 1820-1825. (Pubitemid 351439423)
27. Bottomley, M. J., A. Cirillo, L. Orsatti, L. Ruggeri, T. S. Fisher, J. C. Santoro, R. T. Cummings, R. M. Cubbon, P. Lo Surdo, A. Calzetta, et al. 2009. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J. Biol. Chem. 284: 1313-1323.
28. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379. (Pubitemid 40530265)
29. Grefhorst, A., M. C. McNutt, T. A. Lagace, and J. D. Horton. 2008. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J. Lipid Res. 49: 1303-1311.
30. Schmidt, R. J., T. P. Beyer, W. R. Bensch, Y. W. Qian, A. Lin, M. Kowala, W. E. Alborn, R. J. Konrad, and G. Cao. 2008. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun. 370: 634-640.
31. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.
32. Liang, H., J. Chaparro-Riggers, P. Strop, T. Geng, J. E. Sutton, D. Tsai, L. Bai, Y. Abdiche, J. Dilley, J. Yu, et al. 2012. Proprotein convertase substilisin/kexin type 9 antagonism reduces low density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther. 340: 228-236.
33. Chaparro-Riggers, J., H. Liang, R. M. Devay, L. Bai, J. E. Sutton, W. Chen, T. Geng, K. Lindquist, M. Galindo Casas, L. M. Boustany, et al. 2012. Increasing serum half-life and extending cholesteroil lowering in vivo by engineering an antibody with pH sensitive binding to PCSK9. J. Biol. Chem. 287: 11090-11097.
34. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
35. Montgomery, D. L., J. W. Shiver, K. R. Leander, H. C. Perry, A. Friedman, D. Martinez, J. B. Ulmer, J. J. Donnelly, and M. A. Liu. 1993. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 12: 777-783. (Pubitemid 24295353)
36. Krieg, A. M., A. K. Yi, J. Schorr, and H. L. Davis. 1998. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6: 23-27. (Pubitemid 28068882)
37. Ni, Y. G., S. Di Marco, J. H. Condra, L. B. Peterson, W. Wang, F. Wang, S. Pandit, H. A. Hammond, R. Rosa, D. D. Wood, et al. 2011. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol in mice and rhesus monkeys. J. Lipid Res. 52: 78-86.
38. Whitehead, K. A., R. Langer, and D. G. Anderson. 2009. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8: 129-138.
39. Lilly, S. M., and D. J. Rader. 2007. New targets and emerging therapies for reducing LDL cholesterol. Curr. Opin. Lipidol. 18: 650-655. (Pubitemid 350098570)
40. Lopez, D. 2008. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia. Drug News Perspect. 21: 323-330.
41. Lambert, G., M. Krempf, and P. Costet. 2006. PCSK9: a promising therapeutic target for dyslipidemias? Trends Endocrinol. Metab. 17: 79-81.
42. Frank-Kamenetsky, M., A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, et al. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA. 105: 11915-11920.
43. Maione, D., M. Wiznerowicz, P. Delmastro, R. Cortese, G. Ciliberto, N. La Monica, and R. Savino. 2000. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. 11: 859-868. (Pubitemid 30202477)
44. De Benedetti, F., P. Pignatti, M. Vivarelli, C. Meazza, G. Ciliberto, R. Savino, and A. Martini. 2001. In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. J. Immunol. 166: 4334-4340. (Pubitemid 32233714)